Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT06309966) titled 'Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy' on March 8, 2024.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Biohaven Therapeutics Ltd.
Condition:
Focal Epilepsy
Intervention:
Drug: BHV-7000
Drug: BHV-7000
Recruitment Status: Recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: May 13, 2024
Target Sample Size: 390
Countries of Recruitment:
United States
Au...